Skip to main content
UETeM Lab
  • Home
  • Opportunities
  • News
    • Relevant papers
    • Press articles
    • Upcoming lipodystrophy events
  • Projects
  • Publications
  • Team
  • Collaborations
  • Links
  • Contact
  • LipoDDx

Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy

May 14, 2022 at 11:21 am

Bansal et al.

Endocr Pract. 2022 Mar 14;S1530-891X(22)00086-6.

DOI: 10.1016/j.eprac.2022.03.006. Online ahead of print.

https://pubmed.ncbi.nlm.nih.gov/35301125/

Recent Posts

  • A Novel, Heterozygous BSCL2 Variant in Association With Early-Onset Epileptic Encephalopathy
    14 May, 2022
  • Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)
    14 May, 2022
  • Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network
    14 May, 2022
  • Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need
    14 May, 2022
  • Seipin forms a flexible cage at lipid droplet formation sites
    14 May, 2022
  • Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy
    14 May, 2022
  • Type 2 congenital generalized lipodystrophy with a heterozygous missense NOTCH2 mutation
    14 May, 2022
2019 UETeM Laboratory